Clinical Trials
3
Active:0
Completed:3
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC
Phase 1
Completed
- Conditions
- Punctate Palmoplantar Keratoderma Type 1Pachyonychia Congenita
- Interventions
- Drug: KM-001 cream 1% 12 weeks treatment.Diagnostic Test: Physical ExaminationDiagnostic Test: Vital SignsDiagnostic Test: Serum chemistryDiagnostic Test: HematologyDiagnostic Test: SerologyDiagnostic Test: UrinalysisDiagnostic Test: ECG testDiagnostic Test: Pharmacokinetics AssessmentsDiagnostic Test: Clinical global impression of severity (CGI-S)Diagnostic Test: Visual Analogue Scale (VAS) pain scaleDiagnostic Test: Peak pruritus-numerical rating scale (PP-NRS)Diagnostic Test: Patient global impression of change (PGI-C) scoringDiagnostic Test: Patient global impression of severity (PGI-S) scoringDiagnostic Test: Lesion photographyDrug: KM-001 cream 1% 16 weeks treatment.
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Kamari Pharma Ltd
- Target Recruit Count
- 18
- Registration Number
- NCT05956314
- Locations
- 🇬🇧
Royal London Hospital-Clinical Research Facility-11D (11th Floor) Whitechapel, London, E1 1FR,, London, Whitechapel Rd, United Kingdom
KM-001 Cream for Treatment of Pruritus in Adult Patients With Lichen Simplex Chronicus (LSC)
Phase 1
Completed
- Conditions
- Lichen Simplex Chronicus
- Interventions
- Drug: IMP Application KM-001Diagnostic Test: ChemistryDiagnostic Test: HematologyDiagnostic Test: UrinalysisDiagnostic Test: SerelogyDiagnostic Test: 12-Lead ECGDiagnostic Test: Pregnancy testDiagnostic Test: Blood PK samplingProcedure: Physical ExaminationProcedure: Vital signaDiagnostic Test: Investigator's Global AssessmentDiagnostic Test: Itch Assessment via PP-NRSjOther: E-diary data
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Kamari Pharma Ltd
- Target Recruit Count
- 55
- Registration Number
- NCT05454462
- Locations
- 🇩🇪
Fachklinik Bad Bentheim - Dermatologische Studienambulanz, Bensheim, Germany
🇩🇪Rothhaar Studien GmbH, Berlin, Germany
Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases
Phase 1
Completed
- Conditions
- Punctate Palmoplantar Keratoderma Type 1Pachyonychia Congenita
- Interventions
- Diagnostic Test: Serum chemistryDiagnostic Test: HematologyDiagnostic Test: UrinalysisDiagnostic Test: Physical ExaminationDiagnostic Test: Vital SignsDiagnostic Test: ECG TestDiagnostic Test: PKDiagnostic Test: IGA scoringDrug: KM-001 1% cream 12 weeks treatmentDiagnostic Test: Clinician global impression of severity (CGI-S)Diagnostic Test: Visual Analogue Scale (VAS)Diagnostic Test: Patient global impression of change (PGI-C) scoringDiagnostic Test: Patient global impression of severity (PGI-S) scoringDiagnostic Test: Lesion photographyDrug: KM-001 1% cream 16 weeks treatment
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Kamari Pharma Ltd
- Target Recruit Count
- 14
- Registration Number
- NCT05435638
- Locations
- 🇮🇱
Soroka Medical Center, Beer-Sheva, Israel
🇮🇱Rabin Medical Center (Beilinson, Hasharon), Petah Tikva, Israel
🇮🇱Sourasky Medical Center - Ichilov Hospital, Tel Aviv, Israel
News
No news found